2012-09-24 19:12:33 -

By Jake King

The FDA has scheduled an advisory committee meeting for Ampligen, a product
developed by Hemispherx Biopharma (AMEX:HEB) for the treatment of Chronic
Fatigue Syndrome (CFS), sending shares up by 5% on Monday morning. The meeting
will be held on December 20, followed by a previously-announced February
2, 2013 PDUFA date. In Monday's related press release from HEB, the company also
pointed to an article from "The Pink Sheet" Daily that discusses the FDA's new
statutory provisions for expedited approval of some disease areas, including
CFS.  Ampligen is currently in trials for a variety of immune diseases,
including HIV, CFS, and Avian Flu, and the stock has been seeing increased
trading volume in the last few months as news of Ampligen's development process
is resurrected by the media.

The compound,   however, has a long history in development; a New Drug Application
for the product was filed back in October of 2007, nearly five years ago, for
the same indication that it is now being reviewed. What happened? The FDA
rejected the NDA, saying it was incomplete and cited fourteen deficiencies in
the application. It took a half year for the FDA to accept the resubmitted
application, after which the agency issued a Complete Response Letter and
requested additional clinical trials. Finally in August of this year, after long
negotiations and extensions to the NDA, the FDA agreed to accept the application
with new analysis of the existing trial data. Bulls cite the FDA's renewed
interest in CFS as a reason to buy into Ampligen, although its poor development
history begs to differ. There are currently no approved products for the
treatment of CFS, so a positive vote at the end of the year could create upside
potential on the chance that Ampligen is approved next year. That potential,
however, is far from realized. Today's gains are premature based on the
announcement alone, and we expect the stock to pull back in the near-term before
a possible run-up into the committee meeting if high volume trading continues.

Click here to see this article at PropThink.com.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at  www.propthink.com.




This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: PropThink via Thomson Reuters ONE
[HUG#1643244]